Accurate Investment Solutions Inc. lifted its stake in Pfizer, Inc. (NYSE:PFE) by 3.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 99,136 shares of the biopharmaceutical company’s stock after purchasing an additional 2,869 shares during the period. Pfizer comprises about 2.7% of Accurate Investment Solutions Inc.’s holdings, making the stock its 20th largest holding. Accurate Investment Solutions Inc.’s holdings in Pfizer were worth $3,330,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the stock. Northstar Group Inc. boosted its holdings in Pfizer by 0.4% in the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 35 shares during the period. Stone House Investment Management LLC boosted its holdings in Pfizer by 0.9% in the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock valued at $245,000 after purchasing an additional 66 shares during the period. Naples Global Advisors LLC boosted its holdings in Pfizer by 0.3% in the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock valued at $840,000 after purchasing an additional 79 shares during the period. Pure Financial Advisors Inc. boosted its holdings in Pfizer by 0.4% in the first quarter. Pure Financial Advisors Inc. now owns 22,091 shares of the biopharmaceutical company’s stock valued at $756,000 after purchasing an additional 84 shares during the period. Finally, Alpha Windward LLC boosted its holdings in Pfizer by 1.1% in the first quarter. Alpha Windward LLC now owns 8,387 shares of the biopharmaceutical company’s stock valued at $287,000 after purchasing an additional 89 shares during the period. Hedge funds and other institutional investors own 69.09% of the company’s stock.

PFE has been the subject of a number of recent research reports. Sanford C. Bernstein set a $39.00 target price on Pfizer and gave the company a “buy” rating in a report on Monday, July 17th. BMO Capital Markets upgraded Pfizer from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $33.00 to $37.00 in a report on Wednesday, August 2nd. UBS AG reiterated a “buy” rating and issued a $38.00 target price on shares of Pfizer in a report on Monday, July 31st. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. Finally, Jefferies Group LLC set a $35.00 target price on Pfizer and gave the company a “neutral” rating in a report on Thursday, August 24th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company’s stock. Pfizer presently has an average rating of “Hold” and a consensus target price of $37.72.

In related news, insider Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the transaction, the insider now owns 124,774 shares in the company, valued at $4,242,316. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. Insiders have sold 426,291 shares of company stock worth $14,475,911 in the last quarter. Company insiders own 0.06% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Accurate Investment Solutions Inc. Buys 2,869 Shares of Pfizer, Inc. (PFE)” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/13/accurate-investment-solutions-inc-buys-2869-shares-of-pfizer-inc-pfe.html.

Pfizer, Inc. (NYSE PFE) traded down 0.523% during mid-day trading on Wednesday, hitting $35.185. The stock had a trading volume of 9,587,237 shares. Pfizer, Inc. has a 12-month low of $29.83 and a 12-month high of $35.75. The firm has a market cap of $209.26 billion, a PE ratio of 25.739 and a beta of 1.00. The company has a 50-day moving average of $33.44 and a 200-day moving average of $33.49.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.64 earnings per share. Analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were issued a dividend of $0.32 per share. The ex-dividend date of this dividend was Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.62%. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.